Scientific Publications

Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma: Pooled analysis of 3 clinical trials

Researchers conducted this post hoc analysis of 3 randomized clinical trials (KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006) to explore the correlation of BRAF wild-type (WT) or BRAF V600E/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy with the response to pembrolizumab.

Read More

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma

Researchers conducted this final analysis of a multicenter, open?label, uncontrolled phase II study to test the long?term safety and effectiveness in treatment?naive Japanese patients with advanced melanoma, including acral or mucosal subtypes, and subsequent therapy after discontinuation of the investigational agents.

Read More
MRV News
Melanoma News
Archive
Menu